Sounds of Science – Episode 11 2022 Year in Review: Our Policy team’s perspectives on the past year in EU Health and a look ahead to 2023 Throughout 2022, there have been successes, challenges, delays and change within the European pharmaceutical industry and we expect… read more
A new initiative to boost research and development into rare and paediatric diseases will launch today [Thursday 8 December] at the European Health Summit. The âRare Disease Moonshotâ is a commitment and collaboration between seven organisations to break down the barriers to finding new treatments and cures… read more
Every month, EUCOPE spotlights a member company and the great work theyâre doing to advance the life sciences industry and drive innovation to serve patients better. In October, we spoke with Ăscar Perez, Chief Officer, Marketing, Pricing & Market Access and Business Development at Ferrer Internacional…. read more
On September 5, 2022, the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) and Bundesverband der Pharmazeutischen Industrie (BPI) organised an online event on the revision of the EU regulatory framework for orphan drugs and its impact on Germany. The upcoming revision was discussed together with patient… read more
This article originally featured in PharmaBoardroom. You can find the original article here. EUCOPEâs Secretary-General Dr. Alexander Natz sees both opportunities and pitfalls with the EU HTA procedure, saying that the next three years will decide the crucial steps and whether the new procedure leads… read more
Every month, EUCOPE spotlights a member company and the great work theyâre doing to advance the life sciences industry and drive innovation to serve patients better. In April, we spoke with Malte Peters, M.D., Chief Research and Development Officer, MorphoSys. Dr. Malte Peters joined MorphoSys in… read more
The European Commission is consulting stakeholders as part of its revision process of two major pieces of legislation, on medicines for rare diseases and paediatric patients. Central to the development of innovative treatments for these specific categories of patients, this revision process represents an important… read more
The European Commission has launched an evaluation of the Orphan Medicinal Product (OMP) and Paediatric Regulations. EUCOPE seizes the opportunity to outline ways to strengthen the EU environment for the development of rare and paediatric disease treatments, of which the Regulation (EC) No 1901/2006 on… read more
The European Commission launched an evaluation of the legislation on medicines for rare diseases and children. EUCOPE seizes the opportunity to outline ways to strengthen the whole EU environment for the development of rare diseases treatments, of which the Regulation (EC) No 141/2000 on orphan… read more
The complexities related to delivering some Advanced Therapy Medicinal Products (ATMPs) most likely will require highly specialized clinical expertise and infrastructures, which currently do not exist in all EU counties. Therefore, relocating or crossing borders often represent the only solution for many patients. A well-developed… read more
Keep up-to-date on all of the most pertinent policy files and regulatory news around the world of European health technologies with our monthly newsletter â the Innovation Eye-View